Located in Guilin National High &
New Tech Industry Development Zone, Guilin Huiang Biochemistry
Pharmaceutical Co Ltd was founded in August 1998 and has been specially
engaged in extracting and developing taxanes products,with Paclitaxel
drug substance (API) as its leading
Huiang is a professional paclitaxel
drug substance manufacturer in China, with an annual output of 400kg.
The natural paclitaxel API and semi-synthesis paclitaxel produced by
Huiang have all obtained national drug registration licenses and GMP
certificates, which’s processes have respectively reached national
leading level and international advanced level.
As a certified high-tech enterprise,
intellectual property rights and advanced processes, to ensure its
products strictly to the highest national quality standards. Due to its
products' high quality, Huiang has become a supplier of statutory
reference standards and impurity reference standards for national
statutory administration. Huiang was also entrusted by national
pharmacopeia committee to be one of the members studying the new
concerned standards in Chinese Pharmacopeia.
Huiang focuses on R&D and
self-directed innovation, and has obtained 4 domestic patents including
one utility model patent and three invention patent. Besides, one
international patent has been being applied for which was authorized in
September 2008 in Swiss and has entered into inspection in USA and
Huiang has 106 employees, among
which 32.8% are professional technical personnel allocated in deferent
departments to adapt the products’ manufacturing.
Huiang developed a new
semi-synthesis project with 7-xylosyl-10-de-paclitaxel as raw material,
making a breakthrough in this field. This project gained the Innovation
Fund For Technology Based Firms and has been inspected and accepted.
To ensure the supply of raw
materials, Huiang built its own plantation in Ziyuan county, Guilin
City, and established a branch with 74 employees including 36
technicians in 2003. The plantation covers 13000 mu of planting land
available and manages under GAP. It has planted 3.75 million media yew
from 2003 to 2005, and 0.3 million Tibet yew from 2018 to 2020.
Huiang’s products occupy over 70%
market shares in Chinese market, purchased by some traditional large
paclitaxel injection factories and lately by some newly factories.
Huiang explores international market actively and has obtained DMF
number of FDA, while the applying for EDMF and COS are ongoing.
Trough years of effort, Huiang has
grown to be a modern pharmaceutical enterprise and earned more important
position in the domestic industry. Now it is the key enterprise of
Guangxi in pharmaceutical field, key enterprise of Guilin in industrial
development, and the Natural Anti-cancer Pharmaceutical Research Center
of the City, honored with the Award of Self-directed Innovation and the
Award of the Technical Improvement by Guilin High & New Industry
Development Zone, and the
First Prize of Science and Technology of the City for its paclitxel
“To make good affordable drugs to the people around the
world forever.” With its own entrepreneurial idea and the philosophy of
quality business, Huiang will continue to work towards its objectives
and certainly expand further in future.
Manufacture License GMP Certificate（new)